Overview
Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) is a neurosteroid metabolite of progesterone that is the most potent endogenous positive allosteric modulator of GABA-A receptors. It is central to the pathophysiology of PMDD and postpartum depression — conditions where abnormal sensitivity to allopregnanolone fluctuations drives mood dysregulation.
PMDD and PPD
- In PMDD, patients have paradoxical sensitivity to allopregnanolone — normal luteal phase rises in allopregnanolone trigger anxiety and dysphoria rather than the expected anxiolytic/sedative effect gao 2023 allopregnanolone gaba receptor pmdd itriyeva 2022 pms pmdd adolescents review.
- Brexanolone (IV allopregnanolone) is FDA-approved for postpartum depression; zuranolone (oral) extends this to MDD sundstrom poromaa 2023 pmdd pharmacology sprm.
- Postpartum depression correlates with the precipitous drop in allopregnanolone at delivery suryawanshi 2022 comprehensive review ppd.
Microbiome Connection
- The gut microbiome modulates steroid hormone metabolism including progesterone→allopregnanolone conversion.
- GABA-producing bacteria (Lactobacillus, Bifidobacterium) interact with the GABAergic system that allopregnanolone modulates — a microbiome-neurosteroid-neurotransmitter axis.
- Dysbiosis-driven inflammation (elevated IL-6, TNF-alpha) alters neurosteroid synthesis enzyme expression.
Cross-References
- gaba — allopregnanolone modulates GABA-A receptors
- serotonin — complementary neuroactive pathway in PMDD/PPD
- estrobolome — steroid hormone metabolism by gut bacteria
- gut brain axis — neurosteroid signaling